**Supplementary Figure 2.** Prevalence of Visceral fat obesity (VFO), sarcopenia (defined by BMI- or height-adjusted SMA), and myosteatosis in non-obese controls and individuals with NAFLD. Asterisk (*) denotes comparison between controls and NAFLD without obesity (**P<0.001 and *P<0.05 by chi-squared test). NAFLD, non-alcoholic fatty liver disease; SMA, skeletal muscle area; BMI, body mass index.